-
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review
•
China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for its in-house developed BCL2 inhibitor ICP-248 has been accepted for review by the National Medical Products Administration (NMPA). ICP-248 is a Category 1 innovative drug with independently held intellectual property rights. Drug ProfileInnoCare plans to…
-
Ascletis Pharma Files IND Application for ASC10 with US FDA
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug (IND) application for ASC10, an oral RNA-dependent RNA polymerase (RdRp) inhibitor being developed to treat COVID-19, with the US FDA following a pre-IND consultation. Drug ProfileASC10 is an orally bioavailable, double prodrug of the antiviral…
-
MabPharm’s CMAB017 Receives NMPA Approval for Clinical Study in Solid Tumors
•
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its Category 1 innovative drug candidate CMAB017 in advanced solid tumors. The trial will include patients with colorectal cancer, head and…
-
Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval from the National Medical Products Administration (NMPA) for its generic version of Pfizer’s Ibrance (palbociclib). The drug can now be used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced…
-
Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China
•
Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China for its oral antiviral drug S-217622, developed through a joint venture with Ping An Life Insurance Company under the name Ping An-Shionogi Co., Ltd. Drug ProfileS-217622 is an oral…
-
InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies
•
Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its targeted protein degrader ICP-490. The drug is approved for use in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and other hematological malignancies. Drug ProfileICP-490, developed through InnoCare’s molecular glue…
-
Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma
•
The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA – targeted chimeric antigen receptor (CAR) T cell therapy and Novartis’ Zolgensma (OAV101) have been awarded breakthrough therapy designations (BTDs). Hrain Bio’s BCMA CAR – T cell is indicated for relapsed / refractory multiple myeloma. The…
-
PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy
•
The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06, an in-house developed chimeric antigen receptor (CAR)-T cell targeting B7-H3, has obtained tacit clinical trial approval for relapsed/refractory neuroblastoma. This approval signifies that the world’s first B7-H3 CAR-T therapy will enter the regulatory study phase.…
-
Akeso Biopharma’s Cadonilimab Achieves National Delivery in China
•
China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking a commercial launch just six days after approval. The drug, conditionally approved in China on June 29th, is a self-discovered bispecific antibody (BsAb) indicated for the treatment of recurrent or metastatic cervical cancer that has…
-
Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment
•
The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV: SOBIN) market filing for its anakinra (trade name: Kineret) has been prioritized for review. The drug is indicated for autoinflammatory periodic fever syndrome (familial Mediterranean fever – FMF) in adults, adolescents, children, and infants eight…
-
Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia
•
China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III clinical study for its ARVN003, a proprietary pilocarpine formulation leveraging its micro-dosing platform Optejet. The study aims to evaluate the efficacy and safety of ARVN003 in temporarily improving vision in adults with presbyopia (long-sightedness) in…
-
JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma
•
China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for its JWATM204 in patients with advanced hepatocellular carcinoma (HCC). This first-in-human study aims to evaluate the safety, tolerability, dose-limiting toxicity, and pharmacokinetic profile of JWATM204 in adult subjects with advanced HCC. It will also explore…
-
Brii Biosciences Exercises Option for VIR-3434 in Greater China
•
China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive development and commercialization rights for VIR-3434 (BRII-877) in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. (NASDAQ: VIR). Drug ProfileVIR-3434, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody, is designed to block…
-
Innovent Biologics Doses First Patient in IBI112 Phase II Study for Ulcerative Colitis
•
China-based Innovent Biologics, Inc. (HKG: 1801) announced the successful first patient dosing in a Phase II clinical study (clinicaltrials.gov: NCT05377580) for its IBI112, a recombinant anti-interleukin 23p19 subunit antibody, in moderate-to-severe active ulcerative colitis (UC). The multi-center, randomized, double-blind, parallel, placebo-controlled Phase II clinical study aims to evaluate the efficacy,…
-
Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
•
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study of its PI3K-α inhibitor RP903 (JS105) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative, PIK3CA-mutated advanced or metastatic…
-
InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production
•
Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in Guangzhou has been approved for the commercial manufacturing of its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib. The plant, located in Sino-Singapore Guangzhou Knowledge City, is compliant with Good Manufacturing Practice (GMP) standards in China, Japan,…
-
Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval from the National Medical Products Administration (NMPA) for its generic version of Astellas’s tacrolimus. The drug is approved for use in the prevention of graft rejection after kidney transplantation, prevention of graft rejection in the…
-
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a Phase I clinical study for its ABSK061, an oral highly selective FGFR2/3 inhibitor, in solid tumors. The molecule is described as the first of its kind globally to reach the clinical stages. Study DetailsThe study,…
-
Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in a clinical study for its PD-L1 antibody ASC22 (envafolimab) in combination with chidamide for the functional cure of human immunodeficiency virus (HIV) infection. The study was initiated by the Shanghai Public Health Clinical Center. This…
-
Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials
•
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical Products Administration (NMPA) for its BAT8010 to enter clinical trials for the treatment of general solid tumors. The drug, independently developed by Bio-Thera, is an HER2-targeted antibody-drug conjugate (ADC) consisting of a recombinant humanized anti-HER2…
